Narrowing losses and steady royalty income support the ongoing strategic review. Monitor for any announcement of a strategic transaction or further cash conservation measures, as current cash provides limited runway.
Price Chart
Executive Summary
Xenetic Biosciences reported Q1 2026 results with royalty revenue up 36% YoY to ~$0.8M and net loss narrowing 49% to ~$0.5M, driven by increased Takeda sublicense payments. The company ended the quarter with $7.3M cash while continuing its strategic review process.
Key Financial Metrics
Key Facts
- Royalty revenue increased ~36% YoY to ~$0.8M from ~$0.6M
- Net loss decreased ~49% to ~$0.5M from ~$0.9M in prior year
- Cash and equivalents were ~$7.3M, down from ~$7.9M at Dec 31, 2025
- R&D expenses decreased ~25% to ~$0.7M; G&A decreased ~1.4% to ~$0.6M
Financial Impact
Royalty revenue growth of ~$200K and net loss improvement of ~$400K year-over-year; cash burn ~$200K per month
Risk Factors
- Limited cash runway of approximately 9 months at current burn rate
- Uncertain outcome of strategic review process
- Dependence on single sublicense agreement with Takeda for royalty revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-003766 |
| Document: xenetic_ex9901.htm | 0001683168-26-003766 |
| Document: 0001683168-26-003766-index-headers.html | 0001683168-26-003766 |
| Document: 0001683168-26-003766-index.html | 0001683168-26-003766 |
| Document: 0001683168-26-003766.txt | 0001683168-26-003766 |
| 8-K Data (Synthetic) | 0001683168-26-003766 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $2.47 $1.93 | ▼ −21.86% | ▼ −21.44% | $1.85 (−25.10%) |
Sep 18, 2026 5w ago | SC 13G | $2.77 $1.99 | ▼ −28.16% | ▼ −28.36% | $1.85 (−33.21%) |
Sep 16, 2026 5w ago | 8-K | $2.19 $2.10 | ▼ −4.11% | ▼ −7.29% | $1.85 (−15.53%) |
Aug 7, 2026 11w ago | 8-K | $3.17 $4.67 | ▲ +47.32% | ▲ +47.72% | $1.85 (−41.64%) |
May 13, 2026 23w ago | 8-K | $3.18 $3.00 | ▼ −5.66% | ▼ −5.05% | $1.85 (−41.82%) |
Apr 24, 2026 26w ago | 10-K/A | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.85 (−38.94%) |
Apr 24, 2026 26w ago | 8-K | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.85 (−38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers